文献速递肿瘤 PET/CT神经核医学

生长抑素受体靶向PET/CT可区分头颈部副神经节瘤的不同亚型

Somatostatin Receptor-Directed PET/CT Can Differentiate Between Different Subtypes of Head and Neck Paragangliomas.
PubMed 文献 · Clin Nucl Med · 2023-09-21

14例头颈部副神经节瘤(HNPGL)患者接受68Ga-DOTATOC生长抑素受体(SSTR)PET/CT,视觉评估均可识别原发灶;定量分析显示颈静脉副神经节瘤(PGL-J)的SUVmax和靶本比(TBR)较高,TBR可进一步区分颈动脉副神经节瘤(PGL-C)与伴SDHx胚系变异的PGL-C(PGL-C-SDH)。

要点

  • SSTR-PET/CT可识别所有HNPGL原发灶并发现转移灶
  • PGL-J的TBR高于PGL-C和PGL-C-SDH,有助于亚型区分
  • PGL-C-SDH患者中2/3可见转移灶

核心结论

  • 在HNPGL患者中,SSTR-PET/CT可识别原发灶和转移灶,并提供显著升高的TBR,提示优异的图像对比度。
  • 基于PET的定量分析可区分不同的HNPGL亚型。

研究设计与样本

  • 14例HNPGL患者接受治疗前68Ga-DOTATOC SSTR-PET/CT。
  • 6例(42.9%)为颈静脉副神经节瘤(PGL-J),5例(35.7%)为颈动脉副神经节瘤(PGL-C),3例(21.4%)为伴SDHx胚系致病变异的PGL-C(PGL-C-SDH)。
  • 对原发肿瘤进行视觉和定量评估,包括SUVmax和靶本比(TBR),并在不同HNPGL亚组间比较定量值。

主要发现

  • 视觉评估中,所有原发HNPGL均可在SSTR-PET/CT上识别。
  • PGL-J的SUVmax为101.7 ± 58.5,高于PGL-C-SDH的13.4 ± 5.6(P < 0.05),但与PGL-C的66.7 ± 27.3相比无显著差异(P = 0.4);PGL-C与PGL-C-SDH相比P = 0.2。
  • PGL-J的TBR为202.9 ± 82.2,高于PGL-C的95.7 ± 45.4(P < 0.05)和PGL-C-SDH的20.4 ± 12.2(P < 0.01);PGL-C与PGL-C-SDH相比P = 0.3。
  • 全身读片显示PGL-C-SDH患者中2/3(66.7%)存在转移灶,其中1例为单个SSTR表达骨骼病灶,另1例为双肺病灶。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given their neuroendocrine origin, head and neck paragangliomas (HNPGLs) can be imaged with somatostatin receptor (SSTR)-directed PET/CT. We aimed to determine whether the in vivo PET signal can differentiate between varying HNPGL subtypes. PATIENTS AND METHODS: Fourteen patients with HNPGL received pretherapeutic SSTR-PET/CTs using 68 Ga-DOTATOC. Six (42.9%) patients had a jugular paraganglioma (PGL-J), 5 (35.7%) were diagnosed with carotid paraganglioma (PGL-Cs), and the remaining 3 patients (21.4%) had PGL-C with pathogenic SDHx germline variants (PGL-C-SDH). A visual and quantitative assessment of the primary tumor on SSTR-PET was performed, including SUV max and target-to-background ratio (TBR). Quantitative values were then compared between subgroups of patients affected with different HNPGL entities. RESULTS: On visual assessment, all primary HNPGLs could be identified on SSTR-PET/CT. Quantification of HNPGL revealed substantially elevated SUV max in PGL-J (101.7 ± 58.5) when compared with PGL-C-SDH (13.4 ± 5.6, P < 0.05), but not when compared with PGL-C (66.7 ± 27.3, P = 0.4; PGL-C vs PGL-C-SDH, P = 0.2). TBR of PGL-J (202.9 ± 82.2), however, further differentiated between PGL-C (95.7 ± 45.4, P < 0.05) and PGL-C-SDH (20.4 ± 12.2, P < 0.01; PGL-C vs PGL-C-SDH, P = 0.3). Moreover, whole-body readout revealed metastases in 2/3 (66.7%) of PGL-C-SDH patients, with a single SSTR-expressing skeletal lesion in one subject and bipulmonary lesions in the other patient. CONCLUSIONS: In patients with HNPGL, SSTR-PET/CT identified the primary and metastatic disease and provides substantially elevated TBR, indicating excellent image contrast. PET-based quantification can also differentiate between varying HNPGL subtypes.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhi Y, Gerhard-Hartmann E, Hartrampf PE, et al. Somatostatin Receptor-Directed PET/CT Can Differentiate Between Different Subtypes of Head and Neck Paragangliomas. Clin Nucl Med. 2023. PMID: 37756444. doi:10.1097/RLU.0000000000004870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。